AstraZeneca signs up Regulus in microRNA deal

Regulus Therapeutics, a microRNA-focused drug developer, has added to its impressive roster of pharmaceutical partners by signing a new deal with AstraZeneca.

Regulus Therapeutics, a microRNA-focused drug developer, has added to its impressive roster of pharmaceutical partners by signing a new deal with AstraZeneca.

Under the agreement, which covers three programmes focused on cardiovascular and metabolic diseases and oncology that are currently in preclinical...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category